Syndax Pharmaceuticals (SNDX) is back in focus after highlighting 12 new Revuforj abstracts ahead of the European Hematology Association 2026 Congress, drawing attention to extensive clinical and real-world data across acute leukemia settings.
See our latest analysis for Syndax Pharmaceuticals.
The recent Revuforj data spotlight comes as Syndax’s share price sits at US$20.13, with a year to date share price return down 5.49% but a 1 year total shareholder return of 89.01%, suggesting longer term holders have still seen strong gains even as near term momentum has softened.
If this kind of oncology news has your attention, it may be a good moment to broaden your watchlist and check out 30 healthcare AI stocks
With the stock at US$20.13, a value score of 4, and analyst targets and intrinsic models sitting well above the current price, the key question is whether this represents a buying opportunity or if the market is already pricing in future growth.
Most Popular Narrative: 49% Undervalued
At $20.13, the most followed narrative anchors on a fair value of $39.50, applying a 7.46% discount rate to Syndax's projected cash flows.
Late-stage pipeline advancements (including frontline trials, lifecycle management, and expansion into new indications like IPF for Niktimvo), coupled with strong clinical data and market-leading positions in precision oncology, provide robust long-term growth avenues aligned with surging demand for targeted therapies, supporting sustained multi-year earnings momentum.
Curious what underpins that fair value gap? The narrative leans on rapid revenue expansion, a sharp swing from losses to profitability, and a premium earnings multiple that many investors usually reserve for mature leaders. The exact mix of growth assumptions, margin uplift, and future valuation is where the story really gets interesting.
Result: Fair Value of $39.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the story can change quickly if Revuforj or Niktimvo face clinical or regulatory setbacks, or if rivals pressure pricing and slow the revenue ramp that analysts expect.
Find out about the key risks to this Syndax Pharmaceuticals narrative.
Next Steps
With sentiment clearly focused on upside potential, it makes sense to check the underlying data yourself and move quickly if you disagree or want to lean in. To see what investors are optimistic about, take a closer look at the 2 key rewards
Looking for more investment ideas?
If you are serious about building a stronger portfolio, do not stop at one stock. Use powerful screens to spot opportunities others miss.
- Target potential mispricings by scanning 51 high quality undervalued stocks and see which stocks currently trade below their assessed worth.
- Prioritize resilience by reviewing the solid balance sheet and fundamentals stocks screener (46 results) to focus on companies with healthier financial foundations.
- Get ahead of the crowd by checking the screener containing 21 high quality undiscovered gems that may not yet be widely followed by the market.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com